Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, BridgeBio Pharma Inc’s stock clocked out at $33.02, down -4.48% from its previous closing price of $34.57. In other words, the price has decreased by -$4.48 from its previous closing price. On the day, 2.81 million shares were traded. BBIO stock price reached its highest trading level at $34.5 during the session, while it also had its lowest trading level at $32.84.
Ratios:
To gain a deeper understanding of BBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.67 and its Current Ratio is at 4.67.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when Kumar Neil sold 75,000 shares for $36.87 per share. The transaction valued at 2,764,943 led to the insider holds 4,948,447 shares of the business.
Valantine Hannah sold 12,875 shares of BBIO for $419,500 on Mar 06 ’25. The Director now owns 1,764 shares after completing the transaction at $32.58 per share. On Mar 05 ’25, another insider, KKR Genetic Disorder L.P., who serves as the 10% Owner of the company, sold 6,000,000 shares for $32.96 each. As a result, the insider received 197,760,000 and left with 19,260,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 6280040448 and an Enterprise Value of 7339803648. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.30. Its current Enterprise Value per Revenue stands at 33.077 whereas that against EBITDA is -13.23.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.08, which has changed by 0.12966132 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $39.47, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -3.56%, while the 200-Day Moving Average is calculated to be 16.33%.
Shares Statistics:
It appears that BBIO traded 3.05M shares on average per day over the past three months and 2615250 shares per day over the past ten days. A total of 190.04M shares are outstanding, with a floating share count of 155.43M. Insiders hold about 18.28% of the company’s shares, while institutions hold 76.09% stake in the company. Shares short for BBIO as of 1741910400 were 21759460 with a Short Ratio of 7.14, compared to 1739491200 on 20183599. Therefore, it implies a Short% of Shares Outstanding of 21759460 and a Short% of Float of 17.5.
